Lite Strategy, Inc. Payments of Financing Costs
Lite Strategy, Inc. (LITS) reported Payments of Financing Costs of $0 for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2025-09-26
- Lite Strategy, Inc. payments of financing costs for the quarter ending 2012-06-30 was $0.00.
- Lite Strategy, Inc. payments of financing costs for the quarter ending 2012-03-31 was $0.00.
- Lite Strategy, Inc. payments of financing costs for the quarter ending 2011-12-31 was $9.00K.
- Lite Strategy, Inc. payments of financing costs for the quarter ending 2011-09-30 was $397.00K.
- Lite Strategy, Inc. payments of financing costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Lite Strategy, Inc. payments of financing costs for fiscal 2024 was $208.00K.
- Lite Strategy, Inc. payments of financing costs for fiscal 2023 was $0.00.
- Lite Strategy, Inc. payments of financing costs for fiscal 2018 was $2.40M.
| Period end | Payments of Financing Costs | Payments of Financing Costs 1 month | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month | Payments of Financing Costs 130 month | Payments of Financing Costs 133 month | Payments of Financing Costs 136 month | Payments of Financing Costs 139 month | Payments of Financing Costs 142 month | Payments of Financing Costs 145 month | Payments of Financing Costs 148 month | Payments of Financing Costs 151 month | Payments of Financing Costs 154 month | Payments of Financing Costs 157 month | Payments of Financing Costs 160 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | $0.00 10-K · filed 2025-09-26 | ||||||||||||||||
| 2024-06-30 | $208.00K 10-K · filed 2025-09-26 | ||||||||||||||||
| 2023-06-30 | $0.00 10-K · filed 2024-09-19 | ||||||||||||||||
| 2018-06-30 | $2.40M 10-K · filed 2018-08-30 | ||||||||||||||||
| 2014-03-31 | $406.00K 10-Q · filed 2014-05-08 | ||||||||||||||||
| 2013-12-31 | $406.00K 10-Q · filed 2014-02-11 | ||||||||||||||||
| 2013-09-30 | $406.00K 10-Q · filed 2013-11-08 | ||||||||||||||||
| 2013-06-30 | $406.00K 10-K · filed 2013-09-18 | ||||||||||||||||
| 2013-03-31 | $406.00K 10-Q · filed 2013-05-09 | ||||||||||||||||
| 2012-12-31 | $406.00K 10-Q · filed 2013-02-12 | ||||||||||||||||
| 2012-09-30 | $406.00K 10-Q · filed 2012-11-13 | ||||||||||||||||
| 2012-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-09 | $0.00 derived: sum of 2 quarters · filed 2014-09-09 | $9.00K derived: sum of 3 quarters · filed 2014-09-09 | $406.00K 10-K · filed 2014-09-09 | $406.00K 10-K · filed 2012-09-18 | ||||||||||||
| 2012-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-09 | $9.00K derived: sum of 2 quarters · filed 2013-05-09 | $406.00K 10-Q · filed 2013-05-09 | $406.00K 10-Q · filed 2012-05-15 | |||||||||||||
| 2011-12-31 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-12 | $406.00K 10-Q · filed 2013-02-12 | $406.00K 10-Q · filed 2012-02-09 | ||||||||||||||
| 2011-09-30 | $397.00K 10-Q · filed 2012-11-13 | $397.00K 10-Q · filed 2011-11-14 | |||||||||||||||
| 2011-09-28 | $41.00K 10-K · filed 2014-09-09 | $41.00K 10-K · filed 2013-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |